Mesoblast (MESO) is Becoming Active Gainer on Monday

Many stocks have been flying in premarket trading this morning and the rally in the Mesoblast Limited (NASDAQ: MESO) stock has been quite notable among those.

The stock has soared by a remarkable 70% in premarket trading so far after Mesoblast provided a key update with regards to its heart failure medicine. This morning the company announced that although a clinical trial into the product had not produced mixed results, it is going to go forward and seek approval for it in the United States.

Related:  Agenus (AGEN) Moves In a Range As Investors Await Earnings

It goes without saying it is a significant development for Mesoblast considering the fact that the United States remains the most lucrative market for such products.

However, the company also announced that the data from the Phase 3 trial revealed that the product had been able to substantially reduce the risk of heart attacks, cardiac arrest-related deaths, and strokes. Investors could do well to keep an eye on the Mesoblast stock today following these developments.

Jack Dawkins

Finance and Tech Contributor